glp1versus

Bydureon BCise vs Byetta

exenatide extended-release (GLP-1 receptor agonist) vs exenatide (GLP-1 receptor agonist) — a complete side-by-side comparison.

AstraZenecaAstraZenecaSame active ingredient

Bydureon BCise weight loss

2.3%

Byetta weight loss

2.8%

Bydureon BCise dosing

Once weekly

Byetta dosing

Twice daily (within 60 min before meals)

Reviewed by Dr. Elena Vance, DOLast reviewed 8 sources cited

Quick Summary

Bydureon BCise (exenatide) and Byetta (exenatide) are both glp-1 receptor agonists. In clinical trials, Byetta showed greater weight loss (2.8% vs 2.3%).

See the comparison table below for detailed side-by-side data.

Bydureon BCise vs Byetta: Full Comparison

FeatureBydureon BCise(exenatide extended-release)Byetta(exenatide)
Active Ingredientexenatideexenatide
Drug ClassGLP-1 receptor agonistGLP-1 receptor agonist
ManufacturerAstraZenecaAstraZeneca
FDA Approved2012-01-272005-04-28
Approved Indications
  • Type 2 diabetes mellitus (adjunct to diet and exercise)
  • Type 2 diabetes mellitus (adjunct to diet and exercise)
Routesubcutaneous injectionsubcutaneous injection
FrequencyOnce weeklyTwice daily (within 60 min before meals)
Starting Dose2 mg weekly5 mcg twice daily
Maintenance Dose2 mg weekly10 mcg twice daily
Max Dose2 mg weekly10 mcg twice daily
Weight Loss (%)2.3%2.8%
A1C Reduction1.3%0.8%
Key TrialDURATION-1 (30 weeks)AC2993 Phase 3 (30 weeks)
List Price$800-$950/month$800-$900/month
With Insurance$25-$100/month (varies by plan)$25-$100/month (varies by plan)
Savings CardLimited savings programs availableLimited savings programs available

Side Effects: Bydureon BCise vs Byetta

Side EffectBydureon BCiseByetta
Nausea11%44%
Diarrhea9%13%
Injection site nodule10-17%Not reported
Headache8%9%
Vomiting4%13%
Constipation6%Not reported
Pancreatitis (rare)<1%<1%
DizzinessNot reported9%
DyspepsiaNot reported6%
Jittery feelingNot reported4%

Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.

Related Comparisons

Bydureon BCise vs OzempicByetta vs OzempicBydureon BCise vs WegovyByetta vs WegovyBydureon BCise vs MounjaroByetta vs MounjaroBydureon BCise vs ZepboundByetta vs Zepbound

Frequently Asked Questions

Sources & References

FDA & Regulatory

  1. Bydureon BCise FDA Drugs@FDA approval record — FDA
  2. Byetta FDA Drugs@FDA approval record — FDA

Clinical Trial Records

  1. DURATION-1 clinical trial record — ClinicalTrials.gov
  2. AC2993 Phase 3 clinical trial record — ClinicalTrials.gov

Peer-Reviewed Literature

  1. Drucker DJ et al. Exenatide once weekly versus twice daily for treatment of type 2 diabetes (DURATION-1). Lancet 2008;372:1240-1250 — The Lancet
  2. DeFronzo RA et al. Effects of Exenatide on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients with Type 2 Diabetes. Diabetes Care 2005;28:1092-1100 — Diabetes Care

Manufacturer Information

  1. Bydureon BCise patient website (AstraZeneca) — AstraZeneca

Reference Entries

  1. Exenatide entry on Wikipedia — Wikipedia

This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.